Intravenous propranolol in patients with inflammation.
作者信息
Waller D G, Smith C L, Renwick A G, George C F
出版信息
Br J Clin Pharmacol. 1982 Apr;13(4):577-8. doi: 10.1111/j.1365-2125.1982.tb01426.x.
Abstract
摘要
相似文献
1
Intravenous propranolol in patients with inflammation.炎症患者静脉注射普萘洛尔
Br J Clin Pharmacol. 1982 Apr;13(4):577-8. doi: 10.1111/j.1365-2125.1982.tb01426.x.
2
beta-blocker plasma concentrations and inflammatory disease: clinical implications.
Clin Pharmacokinet. 1982 Jul-Aug;7(4):281-4. doi: 10.2165/00003088-198207040-00001.
3
Early kinetics of intravenous propranolol.静脉注射普萘洛尔的早期动力学
Br J Clin Pharmacol. 1982 Apr;13(4):571-4. doi: 10.1111/j.1365-2125.1982.tb01424.x.
4
Biological determinants of propranolol disposition in man.普萘洛尔在人体中的处置的生物学决定因素。
Clin Pharmacol Ther. 1978 Feb;23(2):165-74. doi: 10.1002/cpt1978232165.
5
The disposition of propranolol. I. Elimination during oral absorption in man.普萘洛尔的处置。I. 人体口服吸收过程中的消除
Pharmacology. 1972;7(3):159-68. doi: 10.1159/000136285.
6
Plasma levels of propranolol in treated patients with coeliac disease and patients with Crohn's disease.患有乳糜泻的患者和患有克罗恩病的患者在接受治疗后血浆中普萘洛尔的水平。
Br Med J. 1976 Oct 2;2(6039):794-5. doi: 10.1136/bmj.2.6039.794.
7
Bioavailability of propranolol in the dog.普萘洛尔在犬体内的生物利用度。
Arch Int Pharmacodyn Ther. 1980 Dec;248(2):180-9.
8
Plasma propranolol concentrations and the erythrocyte sedimentation rate.血浆普萘洛尔浓度与红细胞沉降率。
Br J Clin Pharmacol. 1979 Jul;8(1):43-7. doi: 10.1111/j.1365-2125.1979.tb05907.x.
9
Drug binding to alpha 1-glycoprotein.药物与α1-糖蛋白的结合。
Lancet. 1979 Mar 10;1(8115):554. doi: 10.1016/s0140-6736(79)90974-7.
10
Arterial and venous blood sampling in pharmacokinetic studies: propranolol in rabbits and dogs.
Res Commun Chem Pathol Pharmacol. 1981 Jul;33(1):33-48.
引用本文的文献
1
Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity.药物-疾病相互作用：克罗恩病会提高维拉帕米的血浆浓度，但与疾病活动度成比例地降低药物的反应。
Br J Clin Pharmacol. 2011 Nov;72(5):787-97. doi: 10.1111/j.1365-2125.2011.04019.x.
2
The absorption and conjugation of methyldopa in patients with coeliac and Crohn's diseases during treatment.治疗期间乳糜泻和克罗恩病患者体内甲基多巴的吸收与结合情况
Br J Clin Pharmacol. 1983 Jul;16(1):77-83. doi: 10.1111/j.1365-2125.1983.tb02147.x.
3
The protein binding of timegadine determined by equilibrium dialysis.通过平衡透析法测定替马加汀的蛋白质结合率。
Br J Clin Pharmacol. 1984 Nov;18(5):785-90. doi: 10.1111/j.1365-2125.1984.tb02543.x.
4
Food, drugs, and bioavailability.食物、药物与生物利用度。
Br Med J (Clin Res Ed). 1984 Oct 27;289(6452):1093-4. doi: 10.1136/bmj.289.6452.1093.
5
Pharmacology of propranolol in patients with cirrhosis and portal hypertension.心得安在肝硬化和门静脉高压患者中的药理学研究。
Gut. 1985 Jan;26(1):14-9. doi: 10.1136/gut.26.1.14.
6
Binding to serum alpha 1-acid glycoprotein and effect of beta-adrenoceptor antagonists in rats with inflammation.与血清α1-酸性糖蛋白的结合及β-肾上腺素能受体拮抗剂在炎症大鼠中的作用
Br J Pharmacol. 1986 Jul;88(3):697-705. doi: 10.1111/j.1476-5381.1986.tb10253.x.
本文引用的文献
1
Absorption of propranolol and practolol in Coeliac disease.乳糜泻患者对普萘洛尔和醋氨心安的吸收情况。
Gut. 1976 Feb;17(2):139-43. doi: 10.1136/gut.17.2.139.
2
Plasma levels of propranolol in treated patients with coeliac disease and patients with Crohn's disease.患有乳糜泻的患者和患有克罗恩病的患者在接受治疗后血浆中普萘洛尔的水平。
Br Med J. 1976 Oct 2;2(6039):794-5. doi: 10.1136/bmj.2.6039.794.
3
Plasma binding and the affinity of propranolol for a beta receptor in man.
Clin Pharmacol Ther. 1976 Aug;20(2):152-7. doi: 10.1002/cpt1976202152.
4
High-pressure liquid chromatographic method for the simultaneous quantitative analysis of propranolol and 4-hydroxypropranolol in plasma.
J Chromatogr. 1978 May 1;145(3):429-36. doi: 10.1016/s0378-4347(00)81372-9.
5
Plasma propranolol concentrations and the erythrocyte sedimentation rate.血浆普萘洛尔浓度与红细胞沉降率。
Br J Clin Pharmacol. 1979 Jul;8(1):43-7. doi: 10.1111/j.1365-2125.1979.tb05907.x.
6
Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein.
N Engl J Med. 1978 Dec 28;299(26):1435-9. doi: 10.1056/NEJM197812282992604.
Zotero 插件